$TEM just dropped another record quarter 🔥 Q3 revenue: $411.5M (+23% YoY) Oncology volume growth accelerated to +32% MRD tests: ~12,000 (+300%) Data & Apps revenue: +33% Adjusted EBITDA: $25.6M (vs $1.5M last year) Raised full-year guidance to $1.60–1.605B Cash + securities: $854M Big wins: • Multi-year deal with Merck + Moderna on neoantigen therapy • BMS data licensing → total 2026 data bookings now >$550M • Personalis acquisition cleared regulatory review CEO Eric Lefkofsky: “These results reinforce the durability of our model.” The AI precision medicine flywheel is spinning faster. $TEM up 4% in pre market trading